文献速递肾癌与肾肿瘤

我们是否在使用肾细胞癌分期的最佳肿瘤大小截点?

Are We Using the Best Tumor Size Cut-points for Renal Cell Carcinoma Staging?
PubMed 文献 · Urology · 2017-04-12

该研究纳入1970至2010年间接受根治或部分肾切除术的3304例T1-2Nx/N0M0肾细胞癌患者,比较现行肿瘤大小截点与临床相关替代截点对肿瘤学结局的预测能力。结果发现≤3.0 cm肿瘤的10年无进展生存率和癌症特异性生存率分别为93%-95%和97%-99%,>3.0-4.0 cm者开始下降(91%和95%),不同截点组合的区分度差异很小(c-index 0.691-0.704和0.734-0.750),无充分生物学理由支持某一特定截点。

要点

  • ≤3.0 cm肾细胞癌的10年无进展生存率和癌症特异性生存率分别为93%-95%和97%-99%。
  • 肿瘤>3.0-4.0 cm时无进展生存率和癌症特异性生存率开始下降,分别为91%和95%。
  • 不同肿瘤大小截点组合对进展或肾癌死亡的区分度差异很小。

核心结论

  • ≤3.0 cm的肾细胞癌肿瘤与良好结局相关;此后进展和肾癌死亡风险随肿瘤大小逐渐增加,无充分生物学理由支持某一特定截点优于其他截点。

研究设计与样本

  • 研究纳入1970至2010年间接受根治或部分肾切除术的T1-2Nx/N0M0肾细胞癌患者,共3304例,中位年龄63岁(四分位距53,70)。

主要发现

  • 中位随访时间(存活者)为9.9年(四分位距6.9,14.3),共有536例患者进展,354例死于肾细胞癌。
  • 对于≤3.0 cm的肾细胞癌肿瘤,10年无进展生存率和癌症特异性生存率分别为93%-95%和97%-99%。
  • 对于>3.0-4.0 cm的肿瘤,无进展生存率和癌症特异性生存率开始下降,分别为91%和95%,且随肿瘤增大进一步逐渐下降。
  • 进展和肾癌死亡的风险比随肿瘤大小变化的曲线未显示主要拐点。
  • 基于不同肿瘤大小截点组合对进展或肾癌死亡的区分度差异很小,c-index分别为0.691-0.704和0.734-0.750。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the predictive ability for oncologic outcomes among current tumor size cut-points and clinically relevant alternatives to determine which are optimal. METHODS: Patients who underwent radical or partial nephrectomy between 1970 and 2010 for T1-2Nx/N0M0 renal cell carcinoma (RCC) were identified. Associations between tumor size and progression-free survival (PFS) and cancer-specific survival (CSS) were evaluated using Kaplan-Meier analyses and Cox models. Predictive ability was assessed using c-indexes. RESULTS: The cohort included 3304 patients with a median age of 63 years (interquartile range 53, 70). Median follow-up among survivors was 9.9 years (interquartile range 6.9, 14.3). There were 536 patients who progressed and 354 who died from RCC. For RCC tumors ≤3.0 cm, 10-year PFS and CSS rates were 93%-95% and 97%-99%, respectively. For tumors >3.0-4.0 cm, PFS and CSS began to decline (91% and 95%, respectively), with further gradual declines in PFS and CSS with increasing tumor size. Plots of hazard ratios for progression and RCC death as a function of tumor size did not reveal major inflection points. Differences in discrimination based on various combinations of tumor-size cut-points for progression or RCC death were small, with c-indexes ranging between 0.691-0.704 and 0.734-0.750, respectively. CONCLUSION: RCC tumors ≤3.0 cm in size are associated with favorable outcomes. Thereafter, risks of progression and RCC death increase gradually with tumor size, with no compelling biological reason to endorse a given cut-point over another.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Bhindi B, Lohse CM, Mason RJ, et al. Are We Using the Best Tumor Size Cut-points for Renal Cell Carcinoma Staging? Urology. 2017. PMID: 28412331. doi:10.1016/j.urology.2017.04.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。